{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:05:09Z","timestamp":1790863509734,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2000,8]]},"DOI":"10.1186\/bcr69","type":"journal-article","created":{"date-parts":[[2002,9,26]],"date-time":"2002-09-26T08:07:27Z","timestamp":1033027647000},"source":"Crossref","is-referenced-by-count":19,"title":["Future possibilities in the prevention of breast cancer: Role of genetic variation in breast cancer prevention"],"prefix":"10.1186","volume":"2","author":[{"given":"Heather Spencer","family":"Feigelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2000,8,1]]},"reference":[{"key":"69_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the NationalSurgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093\/jnci\/90.18.1371.","journal-title":"J Natl Cancer Inst"},{"key":"69_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","volume":"352","author":"T Powles","year":"1998","unstructured":"Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the RoyalMarsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998, 352: 98-101.","journal-title":"Lancet"},{"key":"69_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0140-6736(98)85011-3","volume":"352","author":"U Veronesi","year":"1998","unstructured":"Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: preliminary findingsfrom the Italian randomised trial among hysterectomised women. Lancet. 1998, 352: 93-97.","journal-title":"Lancet"},{"key":"69_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S0140-6736(98)85002-2","volume":"352","author":"KI Pritchard","year":"1998","unstructured":"Pritchard KI: Is tamoxifen effective in prevention of breast cancer?[commentary]. Lancet. 1998, 352: 80-81. 10.1016\/S0140-6736(98)85002-2.","journal-title":"Lancet"},{"key":"69_CR5","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","volume":"91","author":"MH Gail","year":"1999","unstructured":"Gail MH, Costantino JP, Bryant J, et al: Weighing the risks and benefits of tamoxifen treatment forpreventing breast cancer. J Natl Cancer Inst. 1999, 91: 1829-1846. 10.1093\/jnci\/91.21.1829.","journal-title":"J Natl Cancer Inst"},{"key":"69_CR6","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausalwomen. Results from the MORE randomized trial. JAMA. 1999, 281: 2189-2197. 10.1001\/jama.281.23.2189.","journal-title":"JAMA"},{"key":"69_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/(SICI)1097-4644(1996)25+<15::AID-JCB2>3.0.CO;2-5","volume":"25","author":"HS Feigelson","year":"1996","unstructured":"Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK, Henderson BE: Genetic susceptibility to cancer from exogenous and endogenousexposures. J Cell Biochem. 1996, 25: 15-22. 10.1002\/(SICI)1097-4644(1996)25+<15::AID-JCB2>3.0.CO;2-5.","journal-title":"J Cell Biochem"},{"key":"69_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/303767a0","volume":"330","author":"MC Pike","year":"1983","unstructured":"Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: Hormonal risk factors, breast tissue age and age-incidence of breastcancer. Nature. 1983, 330: 767-770.","journal-title":"Nature"},{"key":"69_CR9","first-page":"4870","volume":"59","author":"C-S Huang","year":"1999","unstructured":"Huang C-S, Chern H-D, Chang K-J, Cheng C-W, Hsu S-M, Shen C-Y: Breast cancer risk associated with genotype polymorphisms of theestrogen-metabolizing genes CYP17, CYP1A1, and COMT: A multigenic study oncancer susceptibility. Cancer Res. 1999, 59: 4870-4875.","journal-title":"Cancer Res"},{"key":"69_CR10","first-page":"843","volume":"8","author":"AM Dunning","year":"1999","unstructured":"Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DFA: Systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999, 8: 843-854.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"69_CR11","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1210\/mend-4-12-1972","volume":"4","author":"ST Brentano","year":"1990","unstructured":"Brentano ST, Picado-Leonard J, Mellon SH, Moore CC, Miller WL: Tissue-specific, cyclic adenosine3',5'-monophosphate-induced, and phorbol ester-repressedtranscription from the human P450c17 promoter in mouse cells. Mol Endocrinol. 1990, 4: 1972-1979.","journal-title":"Mol Endocrinol"},{"key":"69_CR12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1093\/hmg\/3.10.1873","volume":"3","author":"AH Carey","year":"1994","unstructured":"Carey AH, Waterworth D, Patel K, et al: Polycystic ovaries and premature male pattern baldness areassociated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994, 3: 1873-1876.","journal-title":"Hum Mol Genet"},{"key":"69_CR13","first-page":"1063","volume":"57","author":"HS Feigelson","year":"1997","unstructured":"Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BEA: Polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997, 57: 1063-1065.","journal-title":"Cancer Res"},{"key":"69_CR14","first-page":"585","volume":"58","author":"HS Feigelson","year":"1998","unstructured":"Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE: Cytochrome P450c17alpha gene (CYP17) polymorphism is associated withserum estrogen and progesterone concentrations. Cancer Res . 1998, 58: 585-587.","journal-title":"Cancer Res"},{"key":"69_CR15","first-page":"3908","volume":"59","author":"HS Feigelson","year":"1999","unstructured":"Feigelson HS, McKean-Cowdin R, Pike MC, et al: Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use ofhormone replacement therapy. Cancer Res. 1999, 59: 3908-3910.","journal-title":"Cancer Res"},{"key":"69_CR16","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1038\/bjc.1998.340","volume":"77","author":"AM Dunning","year":"1998","unstructured":"Dunning AM, Healey CS, Pharoah PD, et al: No association between a polymorphism in the steroid metabolism geneCYP17 and risk of breast cancer. Br J Cancer. 1998, 77: 2045-2047.","journal-title":"Br J Cancer"},{"key":"69_CR17","first-page":"945","volume":"7","author":"KJ Helzlsouer","year":"1998","unstructured":"Helzlsouer KJ, Huang HY, Strickland PT, et al: Association between CYP17 polymorphisms and the development ofbreast cancer. Cancer Epidemiol Biomarkers Prev. 1998, 7: 945-949.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"69_CR18","first-page":"941","volume":"7","author":"A Weston","year":"1998","unstructured":"Weston A, Pan CF, Bleiweiss IJ, et al: CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998, 7: 941-944.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"69_CR19","first-page":"1015","volume":"59","author":"CA Haiman","year":"1999","unstructured":"Haiman CA, Hankinson SE, Spiegelman D, et al: The relationship between a polymorphism in CYP17 with plasma hormonelevels and breast cancer. Cancer Res. 1999, 59: 1015-1020.","journal-title":"Cancer Res"},{"key":"69_CR20","first-page":"2825","volume":"59","author":"VN Kristensen","year":"1999","unstructured":"Kristensen VN, Haraldsen EK, Anderson KB, et al: CYP17 and breast cancer risk: the polymorphism in the 5'flanking area of the gene does not influence binding to Sp-1. Cancer Res. 1999, 59: 2825-2828.","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr69.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/bcr69\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr69.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T06:49:25Z","timestamp":1484722165000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1186\/bcr69","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]},"article-number":"277"}}